In vivo evidence that constitutive activity of serotonin2C receptors in the medial prefrontal cortex participates in the control of dopamine release in the rat nucleus accumbens: differential effects of inverse agonist versus antagonist.
about
SB 206553, a putative 5-HT2C inverse agonist, attenuates methamphetamine-seeking in ratsMirtazapine, and mirtazapine-like compounds as possible pharmacotherapy for substance abuse disorders: evidence from the bench and the bedsideSerotonin 5-HT2 receptor interactions with dopamine function: implications for therapeutics in cocaine use disorderThe role of monoamines in the changes in body temperature induced by 3,4-methylenedioxymethamphetamine (MDMA, ecstasy) and its derivativesA 5-HT(2C) receptor antagonist potentiates a low dose amphetamine-induced conditioned place preference.Morphine regulates dopaminergic neuron differentiation via miR-133b.Modafinil reverses phencyclidine-induced deficits in cognitive flexibility, cerebral metabolism, and functional brain connectivityMorphine and microRNA Activity: Is There a Relation with Addiction?Role of the serotonergic system in alcohol dependence: from animal models to clinics.Dispensable, redundant, complementary, and cooperative roles of dopamine, octopamine, and serotonin in Drosophila melanogaster.Striatal serotonin 2C receptors decrease nigrostriatal dopamine release by increasing GABA-A receptor tone in the substantia nigra.Opponency revisited: competition and cooperation between dopamine and serotonin.The role of serotonin in the NMDA receptor antagonist models of psychosis and cognitive impairment.Multiple controls exerted by 5-HT2C receptors upon basal ganglia function: from physiology to pathophysiology.Serotonin2C receptors and drug addiction: focus on cocaine.Synaptic signalling and its interface with neuropathologies: snapshots from the past, present and future.A short history of the 5-HT2C receptor: from the choroid plexus to depression, obesity and addiction treatment.Prediction of Efficacy of Vabicaserin, a 5-HT2C Agonist, for the Treatment of Schizophrenia Using a Quantitative Systems Pharmacology Model.On the Role of Cannabinoid CB1- and μ-Opioid Receptors in Motor Impulsivity.Making Sense of Pharmacology: Inverse Agonism and Functional Selectivity
P2860
Q21262960-2109622E-C059-40A7-9DA7-42FA2D2CD771Q24622161-7EBE98B3-02FA-4778-A5E5-2049A72103E8Q27015917-BF4DA6F7-6AD5-4BD8-A925-366003C4160CQ34112933-C2013A17-4DBA-4941-AD73-8070C3269F88Q34206821-B046D662-1F3E-4C71-83D5-81EF87526E06Q34309942-44C93DBF-FDBF-4B25-8D0A-CAB60CB47905Q35898775-EC21A09E-24C6-49EA-BCC8-188F6F33C69BQ36386234-850D2F8D-D1ED-4CD7-BDFD-DB4D7460AA6AQ36429331-ADE5B95A-5B93-43AF-8EF0-DA3AABF31413Q36480380-A56D029B-D83B-4031-B957-C864106A35EEQ37671124-F7007165-65DE-4CBB-8AE5-4B29E24AE30EQ37794770-7FC34DF0-800F-459C-A211-5D1A8D751D34Q37826638-1C561643-A972-413A-8A6F-2377F50E2C5CQ38101499-274BEEBD-D2F9-4C80-ABCA-D6CFF0C6BF65Q38113111-9C8C4C38-8228-4DDE-A03F-E2CFB617AC05Q38802640-4CE4B0AC-6A6C-4C9B-9A46-914224B81C95Q39164871-7CF3C63C-194D-432A-8C7F-5E0C808F4A9FQ39267434-B471F0DA-CD50-4DD2-BA99-FE08C157B337Q41811043-62B7F038-9203-4D31-A90D-BAF3BF6E4748Q58798205-C6783AF2-A2BC-48F0-A643-21891F06241C
P2860
In vivo evidence that constitutive activity of serotonin2C receptors in the medial prefrontal cortex participates in the control of dopamine release in the rat nucleus accumbens: differential effects of inverse agonist versus antagonist.
description
2009 nî lūn-bûn
@nan
2009 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
In vivo evidence that constitu ...... rse agonist versus antagonist.
@ast
In vivo evidence that constitu ...... rse agonist versus antagonist.
@en
In vivo evidence that constitu ...... rse agonist versus antagonist.
@nl
type
label
In vivo evidence that constitu ...... rse agonist versus antagonist.
@ast
In vivo evidence that constitu ...... rse agonist versus antagonist.
@en
In vivo evidence that constitu ...... rse agonist versus antagonist.
@nl
prefLabel
In vivo evidence that constitu ...... rse agonist versus antagonist.
@ast
In vivo evidence that constitu ...... rse agonist versus antagonist.
@en
In vivo evidence that constitu ...... rse agonist versus antagonist.
@nl
P2093
P1476
In vivo evidence that constitu ...... rse agonist versus antagonist.
@en
P2093
Adeline Cathala
Filippo Drago
Françoise Rouge-Pont
Gian Marco Leggio
Pier Vincenzo Piazza
Umberto Spampinato
P304
P356
10.1111/J.1471-4159.2009.06356.X
P407
P577
2009-08-22T00:00:00Z